Global Chronic Depressive Personality Disorder Treatment Market, By Mechanism of Action (Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)), Drugs (Amitriptyline, Bupropion, Sertraline, Duloxetine), Diagnosis (Physical Exam, Lab Tests and Psychological Evaluation), Treatment (Medication, Psychotherapy), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics Others) - Industry Trends and Forecast to 2030.
Chronic Depressive Personality Disorder Treatment Market Analysis and Size
Chronic depressive personality disorder is also known as dysthymia which is a form of depression that is mild but continuously remains for several years. A patient with chronic depressive personality disorder have symptoms such as lost interest in hopelessness, normal activities, low self-esteem, low appetite, low energy and an overall feeling of inadequacy. These feelings interfere with the patient’s personal and social relationship, profession, and daily activities.
Data Bridge Market Research analyses that the global chronic depressive personality disorder treatment market which was USD 1.49 billion in 2022, is expected to reach USD 6.03 billion by 2030, and is expected to undergo a CAGR of 6.9% during the forecast period of 2023 to 2030. “Selective Serotonin Reuptake Inhibitors (SSRIs)” dominates the mechanism of action segment of the global chronic depressive personality disorder treatment market owing to the rising prevalence of mental disorders surgical procedures. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chronic Depressive Personality Disorder Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
|
|
Countries Covered
|
|
|
Market Players Covered
|
|
|
Market Opportunities
|
|
Market Definition
Persistent symptoms of depression that endure at least two years in adults and one year in children and adolescents are known as chronic depression, also known as Persistent Depressive Disorder (PDD) or dysthymia. Persistent patterns of behaviour, thought, and inner experience that significantly depart from cultural norms are characteristics of personality disorders.
Global Chronic Depressive Personality Disorder Treatment Market Dynamics
Drivers
- Increasing Prevalence of Mental Disorders
The prevalence of chronic depressive disorders and personality disorders is on the rise globally, creating a higher demand for effective treatments.
- Rising Advancements in Psychotherapy
Advances in psychotherapy techniques, such as cognitive-behavioral therapy (CBT), dialectical behavior therapy (DBT), and mindfulness-based therapies, have improved treatment outcomes.
Opportunities
- Growing Demand of Personalized Medicine
There is a growing trend toward personalized treatment plans, tailoring therapies and medications to an individual's specific needs, which can enhance treatment effectiveness.
- Rising Demand of Telehealth
Telehealth and digital mental health platforms have expanded access to treatment, allowing individuals to receive therapy and support remotely.
Restraints/ Challenges
- Cost of Treatment
The cost of long-term mental health treatment, including therapy sessions and medications, can be a barrier for many individuals.
- Lack of Awareness
The stigma associated with mental health issues can deter people from getting help. Reducing stigma and increasing awareness are continuous problems.
- Misdiagnosis and Comorbidity
Accurate diagnosis can be challenging, as conditions like chronic depression often co-occur with personality disorders or other mental health issues. Misdiagnosis can lead to ineffective treatment.
This global chronic depressive personality disorder treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chronic depressive personality disorder treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Chronic Depressive Personality Disorder Treatment Market Scope
Global chronic depressive personality disorder treatment market is segmented on the basis of mechanism of action, drugs, diagnosis, distribution channel and end-users. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Mechanism of action
- Selective serotonin reuptake inhibitors (SSRIs)
- Tricyclic antidepressants (TCAs)
- Serotonin and norepinephrine reuptake inhibitors (SNRIs).
Drugs
- Amitriptyline
- Bupropion
- Sertraline
- Duloxetine
Diagnosis
- Physical Exam
- Lab Tests
- Psychological Evaluation
End-Users
- Hospitals
- Homecare
- Specialty Clinic
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Chronic Depressive Personality Disorder Treatment Market Regional Analysis/Insights
Global chronic depressive personality disorder treatment market is analyzed and market size information is provided by country, mechanism of action, drugs, diagnosis, distribution channel and end-users referenced above.
The countries covered in the global chronic depressive personality disorder treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the global chronic depressive personality disorder treatment market due to changing lifestyle and increasing healthcare expenditure rise in the availability of funds for research, huge patient population, increasing healthcare expenditures, well-developed healthcare sector and government support for research & development in this region.
Asia-Pacific is the expected region in terms of growth in global chronic depressive personality disorder treatment market due to huge patient population, and rise in the presence of huge opportunity in the market in this region.
The country section of the global chronic depressive personality disorder treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Chronic Depressive Personality Disorder Treatment Market Share Analysis
Global chronic depressive personality disorder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global chronic depressive personality disorder treatment market.
Some of the major players operating in the global chronic depressive personality disorder treatment market are:
-
- Pfizer Inc. (U.S.)
- AstraZeneca (U.K.)
- Lilly (U.S.)
- Abiogen Pharma S.p.A. (Italy)
- Merck Sharp & Dohme Corp. (U.S.)
- Novartis AG (Switzerland)
- GlaxoSmithKline plc (U.K.)
- Zimmer Biomet (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Ampio Pharmaceuticals Inc. (U.S.)
- Regeneron Pharmaceuticals Inc. (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Abbott (U.S.)
- AbbVie Inc (U.S.)
- Astellas Pharma Inc. (U.S.)
- BioDelivery Sciences International, Inc. (U.S.)
- Crystal Genomics (South Korea)
- Daiichi-Sankyo Company Limited (Japan)
- Endo Pharmaceuticals Inc (Ireland)
SKU-